IndustryCompany release

OPKO Health to sell BioReference diagnostics to Labcorp for $722M as Q3 revenue rises 16%

🇺🇸 Opko Health, Inc. (OPK) · Wed 04 Nov 2026

OPKO Health agreed to sell its remaining BioReference diagnostic operations to Labcorp and reported third-quarter 2026 continuing-operations revenue of $65.4 million.

OPKO Health said on 4 November 2026 that it has agreed to sell substantially all of its remaining BioReference diagnostic operations to Labcorp. The deal is worth $722 million in cash, plus up to a further $150 million linked to sales of the 4Kscore test.

The transaction is subject to regulatory approvals. The summary on file does not give a closing date or specify which approvals are required.

In its third-quarter 2026 results, published the same day, OPKO reported continuing-operations revenue of $65.4 million, up 16%. The company attributed the growth to royalties from Lilly and to sales of Rayaldee.

OPKO also disclosed a $125 million royalty-note financing with HealthCare Royalty. On the clinical side, it has dosed the first participant in a Phase 1/2a trial of OPK-8801001 in acromegaly.

What it means for your team

  • Regulatory teams tracking diagnostics consolidation should note that the Labcorp sale depends on regulatory approvals, with no timetable given in the available material.
  • Market-access and commercial teams may want to watch how the 4Kscore earn-out of up to $150 million shapes the future commercial handling of that test.
  • Clinical and regulatory professionals following endocrine pipelines can add OPK-8801001 to their watch list, as the Phase 1/2a acromegaly trial has started dosing.

Company's press release (SEC filing): Opko Health, Inc. ↗

Article written by VigiEye from the official source (Opko Health, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →